drugset / Trial / NCT03786484
Study of PBF-999 in Solid Tumour Advanced Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
Multicentric phase I (dose escalation plus expansion) clinical trial of PBF-999 in patients with immunotherapy naïve and pretreated solid tumors to evaluate the safety, tolerability and preliminary efficacy of the compound
Timeline
- Start
- 2017-10-01
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PBF-999 | Small molecule | 20 mg | — |
| Subject | PBF-999 | Small molecule | 40 mg | — |
| Subject | PBF-999 | Small molecule | 80 mg | — |
| Subject | PBF-999 | Small molecule | 120 mg | — |